Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer : the OXEL randomized phase II study
© 2024. The Author(s)..
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) is associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 27. März, Seite 2691 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lynce, Filipa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 08.04.2024 published: Electronic UpdateOf: medRxiv. 2023 Dec 04;:. - PMID 38105958 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-46961-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370281209 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370281209 | ||
| 003 | DE-627 | ||
| 005 | 20240408232858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-46961-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370281209 | ||
| 035 | |a (NLM)38538574 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lynce, Filipa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer |b the OXEL randomized phase II study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Dec 04;:. - PMID 38105958 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) is associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Mainor, Candace |e verfasserin |4 aut | |
| 700 | 1 | |a Donahue, Renee N |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Schlam, Ilana |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongkun |e verfasserin |4 aut | |
| 700 | 1 | |a Toney, Nicole J |e verfasserin |4 aut | |
| 700 | 1 | |a Jochems, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Schlom, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Zeck, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Nanda, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Deena |e verfasserin |4 aut | |
| 700 | 1 | |a Stringer-Reasor, Erica M |e verfasserin |4 aut | |
| 700 | 1 | |a Denduluri, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Chitalia, Ami |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Shruti |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Kaltman, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Khoury, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Gatti-Mays, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Tarantino, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Tolaney, Sara M |e verfasserin |4 aut | |
| 700 | 1 | |a Swain, Sandra M |e verfasserin |4 aut | |
| 700 | 1 | |a Pohlmann, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Parsons, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Isaacs, Claudine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 27. März, Seite 2691 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:27 |g month:03 |g pages:2691 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-46961-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 27 |c 03 |h 2691 | ||